AT2 receptor and apoptosis during AT1 receptor blockade in reperfused myocardial infarction in the rat

Molecular and Cellular Biochemistry

Volumn 262, Issue 1-2, 2004, Pages 203-214

  Jugdutt, Bodh I ^a   Menon, Vijayan ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Angiotensin II receptors; Apoptosis; Echocardiography; In vivo rat model; Left ventricular function; Myocardial infarction; Reperfusion

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN; SODIUM CHLORIDE; TRIPHENYLTETRAZOLIUM; ANGIOTENSIN RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; IMIDAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; TETRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DIASTOLE; DNA DETERMINATION; DRUG MECHANISM; DRUG POTENTIATION; HEART HEMODYNAMICS; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE REPERFUSION; IMMUNOBLOTTING; IN VIVO STUDY; NICK END LABELING; NONHUMAN; RANDOMIZATION; RAT; RAT STRAIN; RECEPTOR BLOCKING; RECEPTOR UPREGULATION; SYSTOLE; ANIMAL; DRUG EFFECT; GENETICS; HEART LEFT VENTRICLE FUNCTION; HEMODYNAMICS; PATHOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; UPREGULATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; APOPTOSIS; BENZIMIDAZOLES; HEMODYNAMIC PROCESSES; IMIDAZOLES; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 2; TETRAZOLES; UP-REGULATION; VENTRICULAR DYSFUNCTION, LEFT;

EID: 4344687432     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:MCBI.0000038236.59905.8b     Document Type: Article

References (55)

1. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, LIFE Study Group: Cardiovascular morbidity and mortality in the Losartan intervention for endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 359: 995-1003, 2002
2. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S, LIFE Study Group: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan intervention for endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 359: 1004-1010, 2002
3. Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345: 1667-1675, 2001
4. Ryan TJ, Antman EM, Brooks NH, Califf RM, Hillis LD, Hiratzka LF, Rapaport E, Riegel B, Russell RO, Smith EE III, Weaver WD, Gibbons RJ, Alpert JS, Eagle KA, Gardner TJ, Garson A Jr, Gregoratos G, Smith SC Jr: ACC/AHA guidelines for the management of patients with acute myocardial infarction: Executive summary and recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation 100: 1016-1030, 1999
5. Reimer KA, Jennings RB: The 'wavefront phenomenon' of myocardial ischemic cell death. II: Transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow. Lab Invest 40: 633-644, 1979
6. Jugdutt BI: Effect of reperfusion on ventricular mass, topography and function during healing of anterior infarction. Am J Physiol 272: H1205-H1211, 1997
7. Braunwald E, Kloner RA: The stunned myocardium: Prolonged, post-ischemic ventricular dysfunction. Circulation 66: 1146-1149, 1982
8. Bolli R: Mechanism of myocardial stunning. Circulation 82: 723-738, 1990
9. Ganz P, Ganz W: Coronary blood flow and myocardial ischemia. In: E. Braunwald, D.P. Zipes, P. Libby (eds.). Heart Disease. 6th edn. W.B. Saunders Company, Philadelphia, Vol 2, 2001, pp 1087-1113
10. Yoshiyama M, Kim S, Yamagishi H, Omura T, Tani T, Yanagi S, Toda I, Teragaki M, Akioka K, Takeuchi K, Takeda T: Cardioprotective effect of the angiotensin II type 1 receptor antagonist TCV-116 on ischemia-reperfusion injury. Am Heart J 128: 1-6, 1994
11. Youhua Z, Shouchun X: Increased vulnerability of hypertrophied myocardium to ischemia and reperfusion injury. Relation to cardiac reninangiotensin system. Chin Med J 108: 28-32, 1995
12. Timmermans PB, Wong PC, Chin AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JA, Smith RD: Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 45: 205-251, 1993
13. 1 receptor blockade in reperfused myocardial infarction. In: N.S. Dhalla (ed). Signal Transduction and Cardiac Hypertrophy Kluwer Academic Publishers, Boston, 2002, pp 221-236
14. Zhu B, Sun Y, Sievers RE, Browne AE, Pulukurthy S, Sudhir K, Lee RJ, Chou TM, Chatterjee K, Parmley WW: Comparative effects of pretreatment with captopril and losartan on cardiovascular protection in a rat model of ischemia-reperfusion. J Am Coll Cardiol 35: 787-795, 2000
15. 2-receptor activation, bradykinin and prostaglandins in pigs. J Am Coll Cardiol 32: 1787-1796, 1998
16. 1 receptor antagonist candesartan at antihypertensive plasma concentrations reduces damage induced by ischemia-reperfusion. Cardiovasc Drugs Ther 13: 347-353, 1999
17. 3 receptor and PKCE proteins. J Renin Angiotensin Aldosterone Syst 1: 184-195, 2000
18. 3R and PKCE proteins and cGMP. J Cardiovasc Pharmacol Therapeut 5: 301-311, 2000
19. 1-receptor blockade after reperfused myocardial intarction. J Renin Angiotensin Aldosterone Syst 2: 134-140, 2001
20. Miyoshi H, Takayama Y, Kitashiro S, Izuoka T, Saito D, Imuro Y, Mimura J, Yamamoto S, Tokioka M, Iwasaka T: Influence of angiotensin II type 1-receptor antagonist CV11974 on infarct size and adjacent regional function after ischemia-reperfusion in dogs. Jpn J Pharmacol 89: 120-125, 2002
21. Yamagishi H, Kim S, Nishikimi T, Takeuchi K, Takeda T: Contribution of cardiac renin-angiotensin system to ventricular remodelling in myocardial-infarcted rats. J Mol Cell Cardiol 25: 1369-1380, 1993
22. Hanatani A, Yoshiyama M, Takeuchi K, Kim S, Nakayama K, Omura T, Iwao H, Yoshikawa J: Angiotensin II type 1-receptor antagonist candesartan cilexitil prevents left ventricular dysfunction in myocardial infarcted rats. Jpn J Pharmacol 78: 45-54, 1998
23. Yoshiyama M, Takeuchi K, Omura T, Kim S, Yamagishi H, Toda I, Teragaki M, Akioka K, Iwao H, Yoshikawa J: Effects of candesartan and cilazapril on rats with myocardial infarction assessed by echocardiography. Hypertension 33: 961-968, 1999
24. Xia QG, Chung O, Spitznagel H, Illner S, Janichen G, Rossius B, Gohlke P, Unger T: Significance of timing of angiotensin AT1 receptor blockade in rats with myocardial infarction-induced heart failure. Cardiovasc Res 49: 110-117, 2001
25. 1) receptor-mediated accumulation of angiotensin II in tissues and its intracellular half-life in vivo. Hypertension 30: 42-49, 1997
26. 2-receptors in endothelial cells and isolated ischemic rat hearts. Pharm Pharmacol Lett 3: 24-27, 1993
27. Liu YH, Yang XP, Sharov VG, Nass O, Sabbah HN, Peterson E, Carretero OA: Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest 99: 1926-1935, 1997
28. Regitz-Zagrosek V, Auch-Shwelk W, Neuss M, Fleck E: Regulation of angiotensin receptor subtypes in cell cultures, animal models and human diseases. Eur Heart J 15: 92-97, 1994
29. Nio Y, Matsubara H, Murasawa S, Kanasaki M, Inada M: Regulation and gene transcription of angiotensin II receptor subtypes in myocardial infarction. J Clin Invest 95: 46-54, 1995
30. Lefroy DC, Wharton J, Crake T, Knock GA, Rutherford RA, Suzuki T, Morgan K, Polak JM, Poole-Wilson PA: Regional changes in angiotensin II receptor density after experimental myocardial infarction. J Mol Cell Cardiol 28: 429-440, 1996
31. Sun Y, Weber KT: Angiotensin II receptor binding following myocardial infarction in the rat. Cardiovasc Res 28: 1623-1628, 1994
32. 2 receptor expression and blockade after acute ischemia-reperfusion in isolated working rat hearts. Am J Physiol 282: H1206-H1215, 2002
33. 1R blockade. Can J Cardiol 18: 1107-1116, 2002
34. Yamada T, Horiuchi M, Dzau VJ: Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Set USA 93: 156-160, 1996
35. Jugdutt BI, Joljart MJ, Khan MI: Rate of collagen deposition during healing after myocardial infarction in the rat and dog models: mechanistic insights into ventricular remodeling. Circulation 94: 94-101, 1996
36. Jugdutt BI, Khan MI, Jugdutt SJ, Blinston GE: Impact of left ventricular unloading after late reperfusion of canine anterior myocardial infarction on remodeling and function using isosorbide-5-mononitrate. Circulation 92: 926-934, 1995
37. Matsumura K, Jeremy RW, Schaper J, Becker LC: Progression of myocardial necrosis during reperfusion of ischemic myocardium. Circulation. 97: 795-804, 1998
38. Feigenbaum H, Popp RL, Wolfe SB, Troy BL, Pombo JF, Haine CL, Dodge HT: Ultrasound measurements of the left ventricle. A correlative study with angiocardiography. Arch Intern Med 129: 461-467, 1972
39. Balghith M, Jugdutt BI: Assessment of diastolic dysfunction after acute myocardial infarction using Doppler Echocardiography. Can J Cardiol 18: 69-77, 2001
40. Zaugg M, Jamali NZ, Lucchinetti E, Shafiq SA, Siddiqui MA: Norepinephrine-induced apoptosis is inhibited in adult rat ventricular myocytes exposed to volatile anesthetics. Anesthesiology 93: 209-218, 2000
41. Moudgil R, Menon V, Xu Y, Musat-Marcu S, Kumar D, Jugdutt BI: Postischemic apoptosis and functional recovery after angiotensin II type 1 receptor blockade in isolated working rat hearts. J Hypertens 19: 1121-1129, 2001
42. 2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension 31: 349-355, 1998
43. 1 antagonists in mice. Hypertension 40: 244-250, 2002
44. Horiuchi M, Akishita M, Dzau VJ: Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension 33: 613-621, 1999
45. Kajstura J, Cigola E, Malhotra A, Li P, Cheng W, Meggs LG, Anversa P: Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. J Moll Cell Cardiol 29: 859-870, 1997
46. Kajstura J, Cheng W, Reiss K, Clark WA, Sonnenblick EH, Krajewski S, Reed JC, Olivetti G, Anversa P: Apoptotic and necrotic myocyte cell deaths are independent contributing variables of infarct size in rats. Lab Invest 74: 86-107, 1996
47. 1 receptor antagonist candesartan. Basic Res Cardiol 94: 208-214, 1999
48. Ohno M, Takemura G, Ohno A, Misao J, Hayakawa Y, Minatoguchi S, Fujiwara T, Fujiwara H: "Apoptotic" myocytes in infarct area in rabbit hearts may be oncotic myocytes with DNA fragmentation. Analysis by immunogold electron microscopy combined with in situ nick end-labeling. Circulation 98: 1422-1430, 1998
49. Kockx MM, Muhring J, Knaapen MWM, de Meyer GRY: RNA synthesis and splicing interferes with DNA in situ end labeling techniques used to detect apoptosis. Am J Pathol 152: 885-888, 1998
50. Kanoh M, Takemura G, Misao J, Hayakawa Y, Aoyama T, Nishigaki K, Noda T, Fujiwara T, Fukuda K, Minatoguchi S, Fujiwara H: Significance of myocytes with positive DNA in situ nick end-labeling (TUNEL) in hearts with dilated cardiomyopathy. Not apoptosis but DNA repair. Circulation 99: 2757-2764, 1999
51. Jugdutt BI, Warnica JW: Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion and complications: Effect of timing, dosage and infarct location. Circulation 78: 906-919, 1988
52. Jugdutt BI: Identification of patients prone to infarct expansion by the degree of regional shape distortion on an early two-dimensional echocardiogram after myocardial intarction. A prospective study. Clin Cardiol 13: 28-40, 1990
53. Lu L, Ko E, Schwartz GG, Chou TM: Transesophageal echocardiography in rats using an intravascular ultrasound catheter. Am J Physiol 273: H2078-H2082, 1997
54. Rohde LE, Ducharme A, Arroyo LH, Aikawa M, Sukhova GH, Lopez-Anaya A, McClure KF, Mitchell PG, Libby P, Lee RT: Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 99: 3063-3070, 1999
55. 2 receptors: Cardiovascular hope or hype? Br J Pharmacol 140: 809-824, 2003